Open AccessAlendronate, Vitamin D, and Calcium for the Treatment of Osteopenia/Osteoporosis Associated With HIV Infection
Author(s) -
Kristin Mondy,
William G. Powderly,
Sherry Claxton,
Kevin E. Yarasheski,
Michael Royal,
John S. Stoneman,
Mary E. Hoffmann,
Pablo Tebas
Publication year - 2005
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/01.qai.0000145352.04440.1e
Subject(s) - medicine , osteopenia , osteoporosis , vitamin d and neurology , bone mineral , bisphosphonate , alendronic acid , vitamin d deficiency , surgery , gastroenterology
Osteopenia and osteoporosis are frequent complications of HIV infection and/or its treatment. Alendronate is the only bisphosphonate approved for the treatment of osteoporosis in men and women. We conducted a 48-week prospective, randomized, open-label study to evaluate the effects of alendronate, vitamin D, and calcium supplementation on bone mineral density (BMD) in patients with HIV infection.